Skip to main content

Profile

Loading content

Ms Claire Bewshea

Exeter IBD and Pharmacogenetics Project Manager

 01392 406850

 RILD Building L3/L06C

 

University of Exeter Medical School, RILD Building, RD&E Hospital Wonford, Barrack Road, Exeter, EX2 5DW, UK

Overview

I am currently  working with Dr Tariq Ahmad, Consultant Gastroenterologist, Royal Devon and Exeter Hospital in delivering multi- centre NIHR  research projects in the field of Inflammatory Bowel Disease (IBD).

I graduated from University of Southampton in 1997 with a BSc (Hons) in  Pharmacology and Physiology. During my  time at Southampton  I also completed a industry placement with Bayer plc, and then went to work and train as a Clinical Research Scientist.   I then relocated to the South West and went on to work for  AstraZeneca until  2006.

From 2008 until 2011 I worked for NHS Devon as a Research and Clinical Trials Manager.

I have been working with Dr Tariq Ahmad since March 2011.

 

 

 

 

Qualifications

BSc (Hons) Pharmacology and Physiology 1997

Clinical Research Scientist 1998

 

Career

Boots 1988-1992

Bayer plc 1995-2002

Astrazeneca 2002-2006

NHS Devon 2008-2011

 

 

 

Links

Research

Research interests

Inflammatory Bowel Disease Genetics of drug side effects anti-TNF response.

Research projects

5ASA - 5- AMINOSALICYLATE INDUCED NEPHROTOXICITY IN IBD PRED4 - Predicting Serious Drug Side Effects in Gastroenterology PANTS- Personalising Anti-TNF Therapy in Crohns Disease.

Research networks

National Institute for Health Research Royal Devon and Exeter Hospital Exeter CRF RD&E Blood Sciences British Society of Gastroenterology Crohn's and Colitis UK International Serious Adverse Event Consortium IBD GENETIC Consortium International IBD Genetics Consortium

Publications

Key publications | Publications by category | Publications by year

Key publications


Walker G, Heap G, Bewshea C, Ahmad T, Irving P, Goodhand J (2016). ANTI-TNF PATIENT TREATMENT PREFERENCES: DATA FROM THE PANTS STUDY.  Author URL.

Publications by category


Journal articles

Carrieri D, Bewshea C, Walker G, Ahmad T, Bowen W, Hall A, Kelly SE (In Press). Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting Report. Journal of Medical Ethics
Sazonovs A, Kennedy N, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea C, Walker G, Perry MH, McDonald TJ, et al (In Press). HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapy.  Abstract.
Masoli JAH, Jeffries A, Temperton B, Auckland C, Michelsen M, Warwick-Dugdale J, Manley R, Farbos A, Ellard S, Knight B, et al (In Press). Viral genetic sequencing identifies staff transmission of COVID-19 is important in a community hospital outbreak.  Abstract.
Chanchlani N, Lin S, Chee D, Hamilton B, Nice R, Arkir Z, Bewshea C, Cipriano B, Derikx LAAP, Dunlop A, et al (2022). Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. J Crohns Colitis, 16(3), 389-397. Abstract.  Author URL.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin K-M, Butler DK, et al (2022). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun, 13(1). Abstract.  Author URL.
Baker S, Dougan G, Hess C, Kingston N, Lehner PJ, Lyons PA, Matheson NJ, Owehand WH, Saunders C, Summers C, et al (2022). Author Correction: SARS-CoV-2 evolution during treatment of chronic infection. Nature, 608(7922), e23-e23.
Baker S, Dougan G, Hess C, Kingston N, Lehner PJ, Lyons PA, Matheson NJ, Owehand WH, Saunders C, Summers C, et al (2022). Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 608(7922), e24-e24.
Alexander JL, Liu Z, Muñoz Sandoval D, Reynolds C, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Anand N, Nice R, et al (2022). COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol, 7(11), 1005-1015. Abstract.  Author URL.
Alexander JL, Kennedy NA, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Liu Z, Nice R, Bewshea C, D'Mello A, et al (2022). COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology & Hepatology, 7(4), 342-352.
Aggarwal D, Page AJ, Schaefer U, Savva GM, Myers R, Volz E, Ellaby N, Platt S, Groves N, Gallagher E, et al (2022). Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission. Nature Communications, 13(1).
Aggarwal D, Warne B, Jahun AS, Hamilton WL, Fieldman T, du Plessis L, Hill V, Blane B, Watkins E, Wright E, et al (2022). Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission. Nature Communications, 13(1). Abstract.
Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, Seaman SR, Harris RJ, Hope R, Lopez-Bernal J, et al (2022). Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. The Lancet Infectious Diseases, 22(1), 35-42. Abstract.
Ellul P, Revés J, Abreu B, Chaparro M, Gisbert JP, Allocca M, Fiorino G, Barberio B, Zingone F, Pisani A, et al (2022). Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: an International Web-based Survey. Journal of Crohn's and Colitis, 16(7), 1070-1078. Abstract.
Alexander J, Kennedy N, Ibraheim H, Anandabaskaran S, Saifuddin A, Seoane RC, Liu Z, Nice R, Bewshea C, D’Mello A, et al (2022). OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab. Journal of Crohn's and Colitis, 16(Supplement_1), i022-i023.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin KM, Butler DK, et al (2022). OP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients. Journal of Crohn's and Colitis, 16(Suppl 1), i023-i025.
Ashford F, Best A, Dunn SJ, Ahmed Z, Siddiqui H, Melville J, Wilkinson S, Mirza J, Cumley N, Stockton J, et al (2022). SARS-CoV-2 Testing in the Community: Testing Positive Samples with the TaqMan SARS-CoV-2 Mutation Panel to Find Variants in Real Time. Journal of Clinical Microbiology, 60(4), e02408-e02421.
Alexander JL, Kennedy N, Ibraheim H, Anandabaskaran S, Saifuddin A, Seoane RC, Liu Z, Nice R, Bewshea CM, D'Mello A, et al (2022). Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB. Gastroenterology, 162(7).
Alexander JL, Mullish BH, Danckert NP, Liu Z, Saifuddin A, Torkizadeh M, Ibraheim H, Blanco JM, Bewshea CM, Nice R, et al (2022). Su1611: POOR RESPONSE TO ANTI-SARS-COV-2 VACCINATION IN IMMUNOSUPPRESSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION. Gastroenterology, 162(7), s-652.
Lin S, Chanchlani N, Carbery I, Janjua M, Nice R, McDonald TJ, Bewshea C, Kennedy NA, Ahmad T, Selinger CP, et al (2022). Understanding. <scp>anti‐TNF</scp>. treatment failure: does serum triiodothyronine‐to‐thyroxine (. <scp>T3</scp>. /. <scp>T4</scp>. ) ratio predict therapeutic outcome to. <scp>anti‐TNF</scp>. therapies in biologic‐naïve patients with active luminal Crohn's disease?. Alimentary Pharmacology & Therapeutics, 56(5), 783-793.
Kennedy NA, Janjua M, Chanchlani N, Lin S, Bewshea C, Nice R, McDonald TJ, Auckland C, Harries LW, Davies M, et al (2022). Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. Gut Abstract.  Author URL.
Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, et al (2021). Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 70(5), 865-875. Abstract.
Chapman TP, Revés J, Torres J, Satsangi J (2021). Anti–SARS-CoV-2 Antibody Responses in Patients with IBD Treated with Biologics: Are We Finding CLARITY?. Gastroenterology, 161(6), 2057-2059.
Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera G, Toole AO, et al (2021). Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. NATURE, 593(7858), 266-+. Author URL.
Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, Kläser K, Canas LS, Molteni E, Modat M, et al (2021). Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. The Lancet Public Health, 6(5), e335-e345.
Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, Davis C, Piccoli L, Pascall DJ, Dillen J, et al (2021). Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 184(5), 1171-1187.e20.
Volz E, Hill V, McCrone JT, Price A, Jorgensen D, O’Toole Á, Southgate J, Johnson R, Jackson B, Nascimento FF, et al (2021). Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell, 184(1), 64-75.e11.
Elliott P, Haw D, Wang H, Eales O, Walters CE, Ainslie KEC, Atchison C, Fronterre C, Diggle PJ, Page AJ, et al (2021). Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. Science, 374(6574). Abstract.  Author URL.
Jackson B, Boni MF, Bull MJ, Colleran A, Colquhoun RM, Darby AC, Haldenby S, Hill V, Lucaci A, McCrone JT, et al (2021). Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic. Cell, 184(20), 5179-5188.e8.
Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, et al (2021). Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 70(10), 1884-1893. Abstract.  Author URL.
Meng B, Kemp SA, Papa G, Datir R, Ferreira IATM, Marelli S, Harvey WT, Lytras S, Mohamed A, Gallo G, et al (2021). Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Reports, 35(13). Abstract.
Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, Hosmillo M, Rees-Spear C, Mlcochova P, Lumb IU, et al (2021). SARS-CoV-2 evolution during treatment of chronic infection. Nature, 592(7853), 277-282. Abstract.
Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, et al (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. NATURE, 593(7857), 136-+. Author URL.
Reuken PA, Andreas N, Grunert PC, Glöckner S, Kamradt T, Stallmach A (2021). T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 16(2), 251-258. Abstract.
Nice R, Chanchlani N, Green H, Bewshea C, Ahmad T, Goodhand JR, McDonald TJ, Perry MH, Kennedy NA (2021). Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays. Aliment Pharmacol Ther, 53(1), 128-137. Abstract.  Author URL.
Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, et al (2020). HLA-DQA1*05 Carriage Associated with Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients with Crohn's Disease. Gastroenterology, 158(1), 189-199. Abstract.  Author URL.
Hamilton B, Green H, Heerasing N, Hendy P, Moore L, Chanchlani N, Walker G, Bewshea C, Kennedy NA, Ahmad T, et al (2020). Incidence and prevalence of inflammatory bowel disease in Devon, UK. Frontline Gastroenterology, 12(6), 461-470. Abstract.
Nice R, Chanchlani N, Green H, Bewshea C, Kennedy N, Ahmad T, Goodhand J, McDonald T, Perry M (2020). OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: the prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service. Journal of Crohn's and Colitis, 14(Supplement_1), s018-s019.
Walker GJ, Chanchlani N, Thomas A, Lin S, Moore L, Heerasing NM, Hendy P, Abdelrahim M, Mole S, Perry MH, et al (2020). Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Arch Dis Child, 105(10), 957-963. Abstract.  Author URL.
Walker GJ, Lin S, Chanchlani N, Thomas A, Hendy P, Heerasing N, Moore L, Green HD, Chee D, Bewshea C, et al (2020). Quality improvement project identifies factors associated with delay in IBD diagnosis. Alimentary Pharmacology & Therapeutics, 52(3), 471-480.
Bewshea CM, Ahmad T, Kennedy N, Weedon M, Harrison J, Walker G, Goodhand J, Jones S (2019). Association of Genetic Variants in NUDT15 with Thiopurine-Induced Myelosuppression in Patients with Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 321 (8), 773-785.
Bewshea CM, Ahmad T, Kennedy N, Goodhand J, McDonald T, Green H (2019). Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterology and Hepatology
(2019). UEG Week 2019 Poster Presentations. United European Gastroenterology Journal, 7(S8), 189-1030.
Kennedy NA, Heap GA, Hamilton B, Walker GJ, Bewshea CM, Bouri S, Goodhand J, Consortium PI, Ahmad T (2018). 159 - Clinical Effectiveness, Safety and Immunogenicity of Anti-TNF Therapy in Crohn's Disease: 12 Month Data from the Pants Study. Gastroenterology, 154(6), s-44.
Walker GJ, Harrison JW, Voskuil MD, Heap GA, Heerasing N, Hendy PJ, Koskela J, Daly MJ, Sokol H, Weersma RK, et al (2018). 472 - NUDT15 Variants Contribute to Thiopurine-Induced Myelosuppression in European Populations. Gastroenterology, 154(6), s-111.
Sazonovs A, Kennedy NA, Bewshea CM, Moutsianas L, Walker GJ, De Lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). 590 - HLA-DQA1 Contributes to the Development of Antibodies to Anti-TNF Therapy in Crohn's Disease. Gastroenterology, 154(6).
Carrieri D, Jackson L, Bewshea C, Prainsack B, Mansfield J, Ahmad T, Hawkins N, Kelly S (2018). Ethical issues in genomic research: Proposing guiding principles co-produced with stakeholders. Clinical Ethics, 13(4), 194-198.
Walker GJ, Moore L, Heerasing N, Hendy P, Perry MH, McDonald TJ, Debenham T, Bethune R, Bewshea C, Hyde C, et al (2018). Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Aliment Pharmacol Ther, 47(8), 1103-1116. Abstract.  Author URL.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De Lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). OP013 HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease. Journal of Crohn's and Colitis, 12(supplement_1), s009-s010.
Kennedy NA, Heap G, Hamilton B, Walker GJ, Bewshea C, Bouri S, Goodhand J, Ahmad T (2018). OP031 Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s disease: 12-month data from the PANTS study. Journal of Crohn's and Colitis, 12(supplement_1), s021-s021.
Walker G, Harrison J, Voskuil M, Heap G, Heerasing N, Hendy P, Koskela J, Daly M, Sokol H, McGovern D, et al (2018). OP035 NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations. Journal of Crohn's and Colitis, 12(supplement_1), s025-s026.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand J, Kennedy NA (2018). P793 Prevalence and phenotype of inflammatory bowel disease across primary and secondary care: Implications for colorectal cancer surveillance. Journal of Crohn's and Colitis, 12(supplement_1), s512-s513.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea CM, Ahmad T, Goodhand J, Kennedy NA (2018). Su1875 - Prevalence and Phenotype of Inflammatory Bowel Disease Across Primary and Secondary Care: Implications for Colorectal Cancer Surveillance. Gastroenterology, 154(6).
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Vito A, Beckly J, Buurman D, Chaudhary R, et al (2017). Corrigendum: Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis, 11(12). Author URL.
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Annese V, Beckly J, Buurman D, Chaudhary R, et al (2016). Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis, 10(2), 149-158. Abstract.  Author URL.
Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, et al (2015). Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature Genetics, 47(9), 979-986.
Perry M, Bewshea C, Brown R, So K, Ahmad T, McDonald T (2015). Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. Ann Clin Biochem, 52(Pt 6), 672-674. Abstract.  Author URL.
Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA, Bell S, Cole A, et al (2014). 6 Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants. Gastroenterology, 146(5), s-2.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 46(10), 1131-1134. Abstract.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet, 46(10), 1131-1134. Abstract.  Author URL.
So K, Bewshea CM, Heap GA, Muller AF, Delaney MP, Daneshmend TK, Hart AL, Orchard TR, Irving PM, D'Souza R, et al (2013). 638 5-Aminosalicylate (5-ASA) Induced Nephrotoxicity in Inflammatory Bowel Disease. Gastroenterology, 144(5), s-112.

Conferences

Alexander J, Mullish B, Danckert N, Liu Z, Saifuddin A, Torkizadeh M, Ibraheim H, Miguens-Blanco J, Bewshea C, Nice R, et al (2022). P2 COVID-19 vaccination response in immunosuppressed patients with IBD is associated with altered gut microbiota function. Poster presentations.
Kennedy NA, Goodhand J, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft N, et al (2021). Anti-SARS-CoV2 antibody responses are attenuated in patients with Inflammatory Bowel Disease treated with infliximab.  Author URL.
Lin S, Bewshea C, Chanchlani N, Chee D, Pollok RC, Kennedy NA, Ahmad T, Goodhand JR (2021). Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic.  Author URL.
Nice R, Chanchlani N, Kennedy NA, Green HD, Lin S, Gordon C, Chee D, Hamilton B, Bewshea C, Goodhand J, et al (2021). POSITIVITY THRESHOLDS OF TOTAL INFLIXIMAB AND ADALIMUMAB ANTI-DRUG ANTIBODY ASSAYS AND IMPACT IN CLINICAL PRACTICE.  Author URL.
Nice R, Chanchlani N, Green H, Bewshea C, Kennedy N, Ahmad T, Goodhand J, McDonald T, Perry M (2020). Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: the prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service.  Author URL.
Walker G, Lin S, Thomas A, Chanchlani N, Moore L, Hendy P, Heerasing N, Green H, Mole S, Bewshea C, et al (2019). PROSPECTIVE COHORT TO IDENTIFY FACTORS ASSOCIATED WITH DIAGNOSTIC DELAY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.  Author URL.
Walker G, Lin S, Chanchlani N, Thomas A, Moore L, Hendy P, Heerasing N, Green H, Bewshea C, Goodhand J, et al (2019). Prospective cohort to identify factors associated with a delay in diagnosis in patients with inflammatory bowel disease.  Author URL.
Kennedy NA, Heap GA, Hamilton B, Walker GJ, Bewshea CM, Bouri S, Goodhand J, Ahmad T, Consortium PANTSI (2018). CLINICAL EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF ANTI-TNF THERAPY IN CROHN'S DISEASE: 12 MONTH DATA FROM THE PANTS STUDY.  Author URL.
Kennedy N, Heap G, Walker G, Bewshea C, Bouri S, Goodhand J, Ahmad T, Consortium PANTSI (2018). CLINICAL EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF ANTI-TNF THERAPY IN CROHN'S DISEASE: 12-MONTH DATA FROM PANTS.  Author URL.
Kennedy NA, Heap G, Hamilton B, Walker GJ, Bewshea C, Bouri S, Goodhand J, Ahmad T, Consortium PANTSI (2018). Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn's disease: 12-month data from the PANTS study.  Author URL.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De lange K, Goodhand JR, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 CONTRIBUTES TO THE DEVELOPMENT OF ANTIBODIES TO ANTI-TNF THERAPY IN CROHN'S DISEASE.  Author URL.
Sazonovs A, Kennedy NA, Bewshea CM, Moutsianas L, Walker GJ, De Lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 CONTRIBUTES TO THE DEVELOPMENT OF ANTIBODIES TO ANTI-TNF THERAPY IN CROHN'S DISEASE.  Author URL.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's disease.  Author URL.
Walker GJ, Harrison JW, Voskuil MD, Heap GA, Heerasing N, Hendy PJ, Koskela J, Daly MJ, Sokol H, Weersma RK, et al (2018). NUDT15 VARIANTS CONTRIBUTE TO THIOPURINE-INDUCED MYELOSUPPRESSION IN EUROPEAN POPULATIONS.  Author URL.
Walker G, Harrison J, Voskuil M, Heap G, Heerasing N, Hendy P, Koskela J, Daly M, Sokol H, McGovern D, et al (2018). NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations.  Author URL.
Hamilton B, Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand JR, Kennedy NA (2018). PREVALENCE AND PHENOTYPE OF IBD ACROSS PRIMARY AND SECONDARY CARE: IMPLICATIONS FOR COLORECTAL CANCER SURVEILLANCE.  Author URL.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea CM, Ahmad T, Goodhand J, Kennedy NA (2018). PREVALENCE AND PHENOTYPE OF INFLAMMATORY BOWEL DISEASE ACROSS PRIMARY AND SECONDARY CARE: IMPLICATIONS FOR COLORECTAL CANCER SURVEILLANCE.  Author URL.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand J, Kennedy NA (2018). Prevalence and phenotype of inflammatory bowel disease across primary and secondary care: Implications for colorectal cancer surveillance.  Author URL.
Hendy P, Heerasing N, Walker G, Heap G, Bewshea C, Kennedy N, Goodhand J, Harrower T, Hobart J, Spiers A, et al (2017). CLINICAL FEATURES OF DEMYELINATION DURING ANTI-TNF THERAPY: PRELIMINARY OUTCOMES OF THE PRED4 STUDY.  Author URL.
Walker GJ, Moore L, Heerasing N, Hendy PJ, Bewshea C, Goodhand JR, Kennedy NA, Calvert C, Ahmad T (2017). CLINICAL VALIDITY AND UTILITY OF FAECAL CALPROTECTIN IN PRIMARY CARE.  Author URL.
Walker GJ, Harrison JW, Heap GA, Heerasing N, Hendy PJ, Bewshea C, Goodhand JR, Weedon MN, Kennedy NA, Ahmad T, et al (2017). NUDT15 VARIANTS CONTRIBUTE TO THIOPURINE-INDUCED MYELOSUPPRESSION IN EUROPEAN POPULATIONS.  Author URL.
Walker G, Heap G, Bewshea C, Ahmad T, Irving P, Goodhand J (2016). ANTI-TNF PATIENT TREATMENT PREFERENCES: DATA FROM THE PANTS STUDY.  Author URL.
Heap G, Bewshea C, Singh A, Weedon M, Goldstein J, Ebney N, Mulgrew C, D'Souza R, Oram R, Orchard T, et al (2014). A genome wide association study identifying association of the MHC region with 5-aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease.  Author URL.
Heap GA, Singh A, Bewshea C, Weedon MN, Cole A, Creed T, Greig E, Irving P, Lindsay J, Mawdsley J, et al (2014). THIOPURINE INDUCED PANCREATITIS IN INFLAMMATORY BOWEL DISEASE: CLINICAL FEATURES AND GENETIC DETERMINANTS.  Author URL.
Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA, Bell S, Cole A, et al (2014). Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants.  Author URL.
So K, Bewshea C, Heap GA, Muller AF, Daneshmend TK, Hart AL, Orchard TR, Irving PM, Russell RK, Wilson DC, et al (2013). 5-AMINOSALICYLATE (5-ASA) INDUCED NEPHROTOXICITY IN INFLAMMATORY BOWEL DISEASE.  Author URL.
So K, Bewshea CM, Heap GA, Muller AF, Delaney MP, Daneshmend TK, Hart AL, Orchard TR, Irving PM, D'Souza R, et al (2013). 5-Aminosalicylate (5-ASA) Induced Nephrotoxicity in Inflammatory Bowel Disease.  Author URL.

Publications by year


In Press

Carrieri D, Bewshea C, Walker G, Ahmad T, Bowen W, Hall A, Kelly SE (In Press). Ethical issues and best practice in clinically based genomic research: Exeter Stakeholders Meeting Report. Journal of Medical Ethics
Sazonovs A, Kennedy N, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea C, Walker G, Perry MH, McDonald TJ, et al (In Press). HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapy.  Abstract.
Dong X, Penrice-Randal R, Goldswain H, Prince T, Randle N, Salguero J, Tree J, Vamos E, Nelson C, Stewart JP, et al (In Press). Identification and quantification of SARS-CoV-2 leader subgenomic mRNA gene junctions in nasopharyngeal samples shows phasic transcription in animal models of COVID-19 and dysregulation at later time points that can also be identified in humans.  Abstract.
Collier DA, De Marco A, Ferreira IATM, Meng B, Datir R, Walls AC, Kemp S SA, Bassi J, Pinto D, Fregni CS, et al (In Press). SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies.  Abstract.
Masoli JAH, Jeffries A, Temperton B, Auckland C, Michelsen M, Warwick-Dugdale J, Manley R, Farbos A, Ellard S, Knight B, et al (In Press). Viral genetic sequencing identifies staff transmission of COVID-19 is important in a community hospital outbreak.  Abstract.

2022

Chanchlani N, Lin S, Chee D, Hamilton B, Nice R, Arkir Z, Bewshea C, Cipriano B, Derikx LAAP, Dunlop A, et al (2022). Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. J Crohns Colitis, 16(3), 389-397. Abstract.  Author URL.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin K-M, Butler DK, et al (2022). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun, 13(1). Abstract.  Author URL.
Baker S, Dougan G, Hess C, Kingston N, Lehner PJ, Lyons PA, Matheson NJ, Owehand WH, Saunders C, Summers C, et al (2022). Author Correction: SARS-CoV-2 evolution during treatment of chronic infection. Nature, 608(7922), e23-e23.
Baker S, Dougan G, Hess C, Kingston N, Lehner PJ, Lyons PA, Matheson NJ, Owehand WH, Saunders C, Summers C, et al (2022). Author Correction: Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature, 608(7922), e24-e24.
Alexander JL, Liu Z, Muñoz Sandoval D, Reynolds C, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Anand N, Nice R, et al (2022). COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. Lancet Gastroenterol Hepatol, 7(11), 1005-1015. Abstract.  Author URL.
Alexander JL, Kennedy NA, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Liu Z, Nice R, Bewshea C, D'Mello A, et al (2022). COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology & Hepatology, 7(4), 342-352.
Aggarwal D, Page AJ, Schaefer U, Savva GM, Myers R, Volz E, Ellaby N, Platt S, Groves N, Gallagher E, et al (2022). Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission. Nature Communications, 13(1).
Aggarwal D, Warne B, Jahun AS, Hamilton WL, Fieldman T, du Plessis L, Hill V, Blane B, Watkins E, Wright E, et al (2022). Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission. Nature Communications, 13(1). Abstract.
Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, Seaman SR, Harris RJ, Hope R, Lopez-Bernal J, et al (2022). Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. The Lancet Infectious Diseases, 22(1), 35-42. Abstract.
Ellul P, Revés J, Abreu B, Chaparro M, Gisbert JP, Allocca M, Fiorino G, Barberio B, Zingone F, Pisani A, et al (2022). Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: an International Web-based Survey. Journal of Crohn's and Colitis, 16(7), 1070-1078. Abstract.
Liu Z, Le K, Zhou X, Alexander JL, Lin S, Bewshea C, Chanchlani N, Nice R, McDonald T, Lamb CA, et al (2022). Neutralising Antibody Potency Against SARS-CoV-2 Ancestral and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease after Three Doses of COVID-19 Vaccine: a Prospective Multicentre Cohort Study (CLARITY).
Alexander J, Kennedy N, Ibraheim H, Anandabaskaran S, Saifuddin A, Seoane RC, Liu Z, Nice R, Bewshea C, D’Mello A, et al (2022). OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab. Journal of Crohn's and Colitis, 16(Supplement_1), i022-i023.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin KM, Butler DK, et al (2022). OP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients. Journal of Crohn's and Colitis, 16(Suppl 1), i023-i025.
Alexander J, Mullish B, Danckert N, Liu Z, Saifuddin A, Torkizadeh M, Ibraheim H, Miguens-Blanco J, Bewshea C, Nice R, et al (2022). P2 COVID-19 vaccination response in immunosuppressed patients with IBD is associated with altered gut microbiota function. Poster presentations.
Ashford F, Best A, Dunn SJ, Ahmed Z, Siddiqui H, Melville J, Wilkinson S, Mirza J, Cumley N, Stockton J, et al (2022). SARS-CoV-2 Testing in the Community: Testing Positive Samples with the TaqMan SARS-CoV-2 Mutation Panel to Find Variants in Real Time. Journal of Clinical Microbiology, 60(4), e02408-e02421.
Alexander JL, Kennedy N, Ibraheim H, Anandabaskaran S, Saifuddin A, Seoane RC, Liu Z, Nice R, Bewshea CM, D'Mello A, et al (2022). Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB. Gastroenterology, 162(7).
Alexander JL, Mullish BH, Danckert NP, Liu Z, Saifuddin A, Torkizadeh M, Ibraheim H, Blanco JM, Bewshea CM, Nice R, et al (2022). Su1611: POOR RESPONSE TO ANTI-SARS-COV-2 VACCINATION IN IMMUNOSUPPRESSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION. Gastroenterology, 162(7), s-652.
Alexander JL, Mullish BH, Danckert NP, Liu Z, Saifuddin A, Torkizadeh M, Ibraheim H, Blanco JM, Roberts LA, Bewshea CM, et al (2022). The gut microbiota and metabolome is associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
Lin S, Chanchlani N, Carbery I, Janjua M, Nice R, McDonald TJ, Bewshea C, Kennedy NA, Ahmad T, Selinger CP, et al (2022). Understanding. <scp>anti‐TNF</scp>. treatment failure: does serum triiodothyronine‐to‐thyroxine (. <scp>T3</scp>. /. <scp>T4</scp>. ) ratio predict therapeutic outcome to. <scp>anti‐TNF</scp>. therapies in biologic‐naïve patients with active luminal Crohn's disease?. Alimentary Pharmacology & Therapeutics, 56(5), 783-793.
Kennedy NA, Janjua M, Chanchlani N, Lin S, Bewshea C, Nice R, McDonald TJ, Auckland C, Harries LW, Davies M, et al (2022). Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. Gut Abstract.  Author URL.

2021

Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, et al (2021). Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 70(5), 865-875. Abstract.
Kennedy NA, Goodhand J, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft N, et al (2021). Anti-SARS-CoV2 antibody responses are attenuated in patients with Inflammatory Bowel Disease treated with infliximab.  Author URL.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin K-M, Butler DK, et al (2021). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients.
Chapman TP, Revés J, Torres J, Satsangi J (2021). Anti–SARS-CoV-2 Antibody Responses in Patients with IBD Treated with Biologics: Are We Finding CLARITY?. Gastroenterology, 161(6), 2057-2059.
Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, Hinsley WR, Laydon DJ, Dabrera G, Toole AO, et al (2021). Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. NATURE, 593(7858), 266-+. Author URL.
Alexander JL, Kennedy NA, Ibraheim H, Anandabaskaran S, Saifuddin A, Seoane RC, Liu Z, Nice R, Bewshea C, D'Mello A, et al (2021). COVID-19 Vaccine-Induced Antibody Responses are Impaired in IBD Patients Treated with Infliximab or Tofacitinib, but not Thiopurines, Ustekinumab or Vedolizumab.
Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, Kläser K, Canas LS, Molteni E, Modat M, et al (2021). Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. The Lancet Public Health, 6(5), e335-e345.
Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, Davis C, Piccoli L, Pascall DJ, Dillen J, et al (2021). Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 184(5), 1171-1187.e20.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds C, Seoane RC, Kottoor S, Pieper F, Lin K-M, Butler DK, et al (2021). Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients.
Lin S, Bewshea C, Chanchlani N, Chee D, Pollok RC, Kennedy NA, Ahmad T, Goodhand JR (2021). Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic.  Author URL.
Volz E, Hill V, McCrone JT, Price A, Jorgensen D, O’Toole Á, Southgate J, Johnson R, Jackson B, Nascimento FF, et al (2021). Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell, 184(1), 64-75.e11.
Elliott P, Haw D, Wang H, Eales O, Walters CE, Ainslie KEC, Atchison C, Fronterre C, Diggle PJ, Page AJ, et al (2021). Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. Science, 374(6574). Abstract.  Author URL.
Jackson B, Boni MF, Bull MJ, Colleran A, Colquhoun RM, Darby AC, Haldenby S, Hill V, Lucaci A, McCrone JT, et al (2021). Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic. Cell, 184(20), 5179-5188.e8.
Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings F, Fraser A, et al (2021). Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines.
Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, et al (2021). Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 70(10), 1884-1893. Abstract.  Author URL.
Nice R, Chanchlani N, Kennedy NA, Green HD, Lin S, Gordon C, Chee D, Hamilton B, Bewshea C, Goodhand J, et al (2021). POSITIVITY THRESHOLDS OF TOTAL INFLIXIMAB AND ADALIMUMAB ANTI-DRUG ANTIBODY ASSAYS AND IMPACT IN CLINICAL PRACTICE.  Author URL.
Meng B, Kemp SA, Papa G, Datir R, Ferreira IATM, Marelli S, Harvey WT, Lytras S, Mohamed A, Gallo G, et al (2021). Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Reports, 35(13). Abstract.
Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, Hosmillo M, Rees-Spear C, Mlcochova P, Lumb IU, et al (2021). SARS-CoV-2 evolution during treatment of chronic infection. Nature, 592(7853), 277-282. Abstract.
Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP, Walls AC, Kemp SA, Bassi J, Pinto D, Silacci-Fregni C, et al (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. NATURE, 593(7857), 136-+. Author URL.
Reuken PA, Andreas N, Grunert PC, Glöckner S, Kamradt T, Stallmach A (2021). T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 16(2), 251-258. Abstract.
Nice R, Chanchlani N, Green H, Bewshea C, Ahmad T, Goodhand JR, McDonald TJ, Perry MH, Kennedy NA (2021). Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays. Aliment Pharmacol Ther, 53(1), 128-137. Abstract.  Author URL.

2020

Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, et al (2020). HLA-DQA1*05 Carriage Associated with Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients with Crohn's Disease. Gastroenterology, 158(1), 189-199. Abstract.  Author URL.
Hamilton B, Green H, Heerasing N, Hendy P, Moore L, Chanchlani N, Walker G, Bewshea C, Kennedy NA, Ahmad T, et al (2020). Incidence and prevalence of inflammatory bowel disease in Devon, UK. Frontline Gastroenterology, 12(6), 461-470. Abstract.
Nice R, Chanchlani N, Green H, Bewshea C, Kennedy N, Ahmad T, Goodhand J, McDonald T, Perry M (2020). OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: the prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service. Journal of Crohn's and Colitis, 14(Supplement_1), s018-s019.
Nice R, Chanchlani N, Green H, Bewshea C, Kennedy N, Ahmad T, Goodhand J, McDonald T, Perry M (2020). Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: the prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service.  Author URL.
Walker GJ, Chanchlani N, Thomas A, Lin S, Moore L, Heerasing NM, Hendy P, Abdelrahim M, Mole S, Perry MH, et al (2020). Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Arch Dis Child, 105(10), 957-963. Abstract.  Author URL.
Walker GJ, Lin S, Chanchlani N, Thomas A, Hendy P, Heerasing N, Moore L, Green HD, Chee D, Bewshea C, et al (2020). Quality improvement project identifies factors associated with delay in IBD diagnosis. Alimentary Pharmacology & Therapeutics, 52(3), 471-480.

2019

Bewshea CM, Ahmad T, Kennedy N, Weedon M, Harrison J, Walker G, Goodhand J, Jones S (2019). Association of Genetic Variants in NUDT15 with Thiopurine-Induced Myelosuppression in Patients with Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 321 (8), 773-785.
Walker G, Lin S, Thomas A, Chanchlani N, Moore L, Hendy P, Heerasing N, Green H, Mole S, Bewshea C, et al (2019). PROSPECTIVE COHORT TO IDENTIFY FACTORS ASSOCIATED WITH DIAGNOSTIC DELAY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE.  Author URL.
Bewshea CM, Ahmad T, Kennedy N, Goodhand J, McDonald T, Green H (2019). Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterology and Hepatology
Walker G, Lin S, Chanchlani N, Thomas A, Moore L, Hendy P, Heerasing N, Green H, Bewshea C, Goodhand J, et al (2019). Prospective cohort to identify factors associated with a delay in diagnosis in patients with inflammatory bowel disease.  Author URL.
(2019). UEG Week 2019 Poster Presentations. United European Gastroenterology Journal, 7(S8), 189-1030.

2018

Kennedy NA, Heap GA, Hamilton B, Walker GJ, Bewshea CM, Bouri S, Goodhand J, Consortium PI, Ahmad T (2018). 159 - Clinical Effectiveness, Safety and Immunogenicity of Anti-TNF Therapy in Crohn's Disease: 12 Month Data from the Pants Study. Gastroenterology, 154(6), s-44.
Walker GJ, Harrison JW, Voskuil MD, Heap GA, Heerasing N, Hendy PJ, Koskela J, Daly MJ, Sokol H, Weersma RK, et al (2018). 472 - NUDT15 Variants Contribute to Thiopurine-Induced Myelosuppression in European Populations. Gastroenterology, 154(6), s-111.
Sazonovs A, Kennedy NA, Bewshea CM, Moutsianas L, Walker GJ, De Lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). 590 - HLA-DQA1 Contributes to the Development of Antibodies to Anti-TNF Therapy in Crohn's Disease. Gastroenterology, 154(6).
Kennedy NA, Heap GA, Hamilton B, Walker GJ, Bewshea CM, Bouri S, Goodhand J, Ahmad T, Consortium PANTSI (2018). CLINICAL EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF ANTI-TNF THERAPY IN CROHN'S DISEASE: 12 MONTH DATA FROM THE PANTS STUDY.  Author URL.
Kennedy N, Heap G, Walker G, Bewshea C, Bouri S, Goodhand J, Ahmad T, Consortium PANTSI (2018). CLINICAL EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF ANTI-TNF THERAPY IN CROHN'S DISEASE: 12-MONTH DATA FROM PANTS.  Author URL.
Kennedy NA, Heap G, Hamilton B, Walker GJ, Bewshea C, Bouri S, Goodhand J, Ahmad T, Consortium PANTSI (2018). Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn's disease: 12-month data from the PANTS study.  Author URL.
Carrieri D, Jackson L, Bewshea C, Prainsack B, Mansfield J, Ahmad T, Hawkins N, Kelly S (2018). Ethical issues in genomic research: Proposing guiding principles co-produced with stakeholders. Clinical Ethics, 13(4), 194-198.
Walker GJ, Moore L, Heerasing N, Hendy P, Perry MH, McDonald TJ, Debenham T, Bethune R, Bewshea C, Hyde C, et al (2018). Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Aliment Pharmacol Ther, 47(8), 1103-1116. Abstract.  Author URL.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De lange K, Goodhand JR, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 CONTRIBUTES TO THE DEVELOPMENT OF ANTIBODIES TO ANTI-TNF THERAPY IN CROHN'S DISEASE.  Author URL.
Sazonovs A, Kennedy NA, Bewshea CM, Moutsianas L, Walker GJ, De Lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 CONTRIBUTES TO THE DEVELOPMENT OF ANTIBODIES TO ANTI-TNF THERAPY IN CROHN'S DISEASE.  Author URL.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's disease.  Author URL.
Walker GJ, Harrison JW, Voskuil MD, Heap GA, Heerasing N, Hendy PJ, Koskela J, Daly MJ, Sokol H, Weersma RK, et al (2018). NUDT15 VARIANTS CONTRIBUTE TO THIOPURINE-INDUCED MYELOSUPPRESSION IN EUROPEAN POPULATIONS.  Author URL.
Walker G, Harrison J, Voskuil M, Heap G, Heerasing N, Hendy P, Koskela J, Daly M, Sokol H, McGovern D, et al (2018). NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations.  Author URL.
Sazonovs A, Kennedy NA, Bewshea C, Moutsianas L, Walker GJ, De Lange K, Goodhand J, Anderson C, Barrett J, Ahmad T, et al (2018). OP013 HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn’s disease. Journal of Crohn's and Colitis, 12(supplement_1), s009-s010.
Kennedy NA, Heap G, Hamilton B, Walker GJ, Bewshea C, Bouri S, Goodhand J, Ahmad T (2018). OP031 Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn’s disease: 12-month data from the PANTS study. Journal of Crohn's and Colitis, 12(supplement_1), s021-s021.
Walker G, Harrison J, Voskuil M, Heap G, Heerasing N, Hendy P, Koskela J, Daly M, Sokol H, McGovern D, et al (2018). OP035 NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations. Journal of Crohn's and Colitis, 12(supplement_1), s025-s026.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand J, Kennedy NA (2018). P793 Prevalence and phenotype of inflammatory bowel disease across primary and secondary care: Implications for colorectal cancer surveillance. Journal of Crohn's and Colitis, 12(supplement_1), s512-s513.
Hamilton B, Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand JR, Kennedy NA (2018). PREVALENCE AND PHENOTYPE OF IBD ACROSS PRIMARY AND SECONDARY CARE: IMPLICATIONS FOR COLORECTAL CANCER SURVEILLANCE.  Author URL.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea CM, Ahmad T, Goodhand J, Kennedy NA (2018). PREVALENCE AND PHENOTYPE OF INFLAMMATORY BOWEL DISEASE ACROSS PRIMARY AND SECONDARY CARE: IMPLICATIONS FOR COLORECTAL CANCER SURVEILLANCE.  Author URL.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea C, Ahmad T, Goodhand J, Kennedy NA (2018). Prevalence and phenotype of inflammatory bowel disease across primary and secondary care: Implications for colorectal cancer surveillance.  Author URL.
Heerasing N, Hendy PJ, Moore L, Walker GJ, Bewshea CM, Ahmad T, Goodhand J, Kennedy NA (2018). Su1875 - Prevalence and Phenotype of Inflammatory Bowel Disease Across Primary and Secondary Care: Implications for Colorectal Cancer Surveillance. Gastroenterology, 154(6).
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, et al (2018). Understanding Anti-TNF Treatment Failure: a Prospective Multi-Centre Study of Biologic Naive Patients with Active Luminal Crohn's Disease.
Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, et al (2018). Understanding Anti-TNF Treatment Failure: a Prospective Multi-Centre Study of Biologic Naïve Patients with Active Luminal Crohn's Disease.

2017

Hendy P, Heerasing N, Walker G, Heap G, Bewshea C, Kennedy N, Goodhand J, Harrower T, Hobart J, Spiers A, et al (2017). CLINICAL FEATURES OF DEMYELINATION DURING ANTI-TNF THERAPY: PRELIMINARY OUTCOMES OF THE PRED4 STUDY.  Author URL.
Walker GJ, Moore L, Heerasing N, Hendy PJ, Bewshea C, Goodhand JR, Kennedy NA, Calvert C, Ahmad T (2017). CLINICAL VALIDITY AND UTILITY OF FAECAL CALPROTECTIN IN PRIMARY CARE.  Author URL.
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Vito A, Beckly J, Buurman D, Chaudhary R, et al (2017). Corrigendum: Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis, 11(12). Author URL.
Walker GJ, Harrison JW, Heap GA, Heerasing N, Hendy PJ, Bewshea C, Goodhand JR, Weedon MN, Kennedy NA, Ahmad T, et al (2017). NUDT15 VARIANTS CONTRIBUTE TO THIOPURINE-INDUCED MYELOSUPPRESSION IN EUROPEAN POPULATIONS.  Author URL.

2016

Walker G, Heap G, Bewshea C, Ahmad T, Irving P, Goodhand J (2016). ANTI-TNF PATIENT TREATMENT PREFERENCES: DATA FROM THE PANTS STUDY.  Author URL.
Heap GA, So K, Weedon M, Edney N, Bewshea C, Singh A, Annese V, Beckly J, Buurman D, Chaudhary R, et al (2016). Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. J Crohns Colitis, 10(2), 149-158. Abstract.  Author URL.

2015

Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A, Ripke S, Lee JC, Jostins L, Shah T, et al (2015). Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nature Genetics, 47(9), 979-986.
Perry M, Bewshea C, Brown R, So K, Ahmad T, McDonald T (2015). Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. Ann Clin Biochem, 52(Pt 6), 672-674. Abstract.  Author URL.

2014

Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA, Bell S, Cole A, et al (2014). 6 Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants. Gastroenterology, 146(5), s-2.
Heap G, Bewshea C, Singh A, Weedon M, Goldstein J, Ebney N, Mulgrew C, D'Souza R, Oram R, Orchard T, et al (2014). A genome wide association study identifying association of the MHC region with 5-aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease.  Author URL.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 46(10), 1131-1134. Abstract.
Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K, Dubois PC, Andrews JM, et al (2014). HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nat Genet, 46(10), 1131-1134. Abstract.  Author URL.
Heap GA, Singh A, Bewshea C, Weedon MN, Cole A, Creed T, Greig E, Irving P, Lindsay J, Mawdsley J, et al (2014). THIOPURINE INDUCED PANCREATITIS IN INFLAMMATORY BOWEL DISEASE: CLINICAL FEATURES AND GENETIC DETERMINANTS.  Author URL.
Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA, Bell S, Cole A, et al (2014). Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants.  Author URL.

2013

So K, Bewshea C, Heap GA, Muller AF, Daneshmend TK, Hart AL, Orchard TR, Irving PM, Russell RK, Wilson DC, et al (2013). 5-AMINOSALICYLATE (5-ASA) INDUCED NEPHROTOXICITY IN INFLAMMATORY BOWEL DISEASE.  Author URL.
So K, Bewshea CM, Heap GA, Muller AF, Delaney MP, Daneshmend TK, Hart AL, Orchard TR, Irving PM, D'Souza R, et al (2013). 5-Aminosalicylate (5-ASA) Induced Nephrotoxicity in Inflammatory Bowel Disease.  Author URL.
So K, Bewshea CM, Heap GA, Muller AF, Delaney MP, Daneshmend TK, Hart AL, Orchard TR, Irving PM, D'Souza R, et al (2013). 638 5-Aminosalicylate (5-ASA) Induced Nephrotoxicity in Inflammatory Bowel Disease. Gastroenterology, 144(5), s-112.

Claire_Bewshea Details from cache as at 2022-12-01 21:13:55

Refresh publications

Teaching

Pharmacology

Inflammatory Bowel Disease.

 

Supervision / Group

Back | Edit Profile